Archive | News

Published Results from Sagimet’s FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640’s Ability to Significantly Reduce Excess Liver Fat

Sagimet

– Secondary analysis showed improvements of metabolic, inflammatory, and fibrotic markers San Mateo, California, July 26, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that Gastroenterology – the official journal of the American Gastroenterological Association – published results from the company’s FASCINATE-1 Phase 2a clinical […]

Comments Off on Published Results from Sagimet’s FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640’s Ability to Significantly Reduce Excess Liver Fat Continue Reading →

CoapTech Receives CE Mark Approval and CPT Procedure Code for Its PUMA-G System

Puma

BALTIMORE, July 14, 2021 /PRNewswire/ — CoapTech, Inc, a medical device company focused on delivering transformative solutions for minimally-invasive surgery, announced today it has received CE Mark certification, as well as an approved CPT Procedure Code for its PUMA-G System, the world’s first and only ultrasound gastrostomy system that allows physicians to place gastrostomy tubes at the point of care, […]

Comments Off on CoapTech Receives CE Mark Approval and CPT Procedure Code for Its PUMA-G System Continue Reading →

GlycoMimetics CEO Rachel King Included Among I95 BUSINESS’ Six Powerful Women Leaders in Life Sciences

Rachel 2018-09-28 Glycomimetics retouch-2-2

Editor’s Note: The Mid-Atlantic region is chocked full of high-profile health care companies that call Maryland home. Many of them are led by brilliant, innovative leaders who just happen to also be women.  Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. Rachel K. King co-founded GlycoMimetics, Inc. (GMI) in 2003 and has served as its CEO […]

Comments Off on GlycoMimetics CEO Rachel King Included Among I95 BUSINESS’ Six Powerful Women Leaders in Life Sciences Continue Reading →

BioTalk Podcast Gets Inside Scoop on RNADD’s Exclusive License to Cutting-Edge Molecular RNA Dx Platform Technology from UMB and UMBC

block

Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join BioTalk to discuss RNA Disease Diagnostics, UM Ventures, and the commercialization of new medical technologies Listen via Apple http://apple.co/3bsUsda, Google http://bit.ly/38l26Vd , Spotify http://spoti.fi/38kp9zu, and TuneIN http://bit.ly/2MVFqDp. Prof. Dipanjan Pan, MS, Ph.D., is an expert in nanomedicine, molecular imaging, drug delivery, and biosensing. He is presently a […]

Comments Off on BioTalk Podcast Gets Inside Scoop on RNADD’s Exclusive License to Cutting-Edge Molecular RNA Dx Platform Technology from UMB and UMBC Continue Reading →

GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer

2019-08-01 Glycomimetics-106_eric feldman

ROCKVILLE, Md.–(BUSINESS WIRE)–Feb. 23, 2021– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development. “Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone […]

Comments Off on GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer Continue Reading →

Sagimet Biosciences Raises $80 Million in Crossover Financing

Sagimet

Altium Capital, HM Capital, Invus, and PFM Health Sciences join previous investors Ascletis, Kleiner Perkins, New Enterprise Associates, Rock Springs Capital, and two undisclosed leading public equity healthcare investors in financing to advance pipeline of FASN inhibitorsCompany also provides update on new board chair and directors San Mateo, California, February 11, 2021 – Sagimet Biosciences, a […]

Comments Off on Sagimet Biosciences Raises $80 Million in Crossover Financing Continue Reading →

RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC

umventures-logo-trans

BALTIMORE, Feb. 4, 2021 /PRNewswire/ — RNA Disease Diagnostics, Inc. (RNADD) has secured an exclusive global license to a cutting-edge sensor technology jointly owned by University of Maryland, Baltimore (UMB) and the University of Maryland, Baltimore County (UMBC). RNADD’s first product will be a rapid point-of-care (POC) COVID-19 test with accuracy, sensitivity, and specificity that is comparable to the gold standard RT-PCR […]

Comments Off on RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC Continue Reading →

Meet Your 2020 BioBuzz Award Winners

BioBuzz-Award-Winners-featured-image

Today, we are excited to announce the winners of our inaugural BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C. The award categories include: The Community Impact Leader […]

MapLight Therapeutics Receives $8.1 Million For Parkinson’s Disease Research

MapLight

SAN FRANCISCO, Nov. 30, 2020 /PRNewswire/ — MapLight Therapeutics today announced a $8.1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to undertake a large-scale, systematic investigation of the brain circuits and mechanisms that are responsible for triggering psychiatric symptoms in Parkinson’s disease. Results will inform identification of novel drug targets and therapeutic strategies to […]

Comments Off on MapLight Therapeutics Receives $8.1 Million For Parkinson’s Disease Research Continue Reading →